ALMS peer analysis
Alumis (ALMS) against its competitors: price, today's move, 1-year return and market value side by side.
ALMS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACRS Aclaris Therapeutics | $4.25 | 8.97% | 87.22% | $674.10M |
| AGMB AgomAb | $7.63 | 9.54% | – | – |
| ALDX Aldeyra Therapeutics | $0.63 | 2.89% | -86.83% | $38.25M |
| ANAB AnaptysBio | $48.02 | 3.38% | 25.71% | $1.44B |
| ARTV Artiva Biotherapeutics | $4.22 | 1.69% | 22.67% | $206.32M |
| AVTX Avalo Therapeutics | $7.26 | 4.83% | -52.89% | $420.08M |
| IFRX InflaRx | $1.30 | -0.38% | 8.33% | $19.35M |
| ODTX Odyssey Therapeutics | $19.12 | -0.57% | – | $919.06M |
| RIGL Rigel Pharmaceuticals | $41.93 | 5.75% | 16.09% | $789.54M |
| TLSA Tiziana Life Sciences | $0.69 | 11.03% | -61.73% | $83.01M |
| ALMS Alumis | $6.54 | 8.46% | 38.56% | $846.51M |
- ALMS's peers: ACRS (Aclaris Therapeutics), AGMB (AgomAb), ALDX (Aldeyra Therapeutics), ANAB (AnaptysBio), ARTV (Artiva Biotherapeutics), AVTX (Avalo Therapeutics), IFRX (InflaRx), ODTX (Odyssey Therapeutics).
Updated 2026-11-10 04:45 UTC